JP2012520342A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520342A5
JP2012520342A5 JP2012500227A JP2012500227A JP2012520342A5 JP 2012520342 A5 JP2012520342 A5 JP 2012520342A5 JP 2012500227 A JP2012500227 A JP 2012500227A JP 2012500227 A JP2012500227 A JP 2012500227A JP 2012520342 A5 JP2012520342 A5 JP 2012520342A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012500227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/053418 external-priority patent/WO2010106082A1/en
Publication of JP2012520342A publication Critical patent/JP2012520342A/ja
Publication of JP2012520342A5 publication Critical patent/JP2012520342A5/ja
Pending legal-status Critical Current

Links

JP2012500227A 2009-03-16 2010-03-16 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート Pending JP2012520342A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16064209P 2009-03-16 2009-03-16
US61/160,642 2009-03-16
US17795809P 2009-05-13 2009-05-13
US61/177,958 2009-05-13
US22762009P 2009-07-22 2009-07-22
US61/227,620 2009-07-22
PCT/EP2010/053418 WO2010106082A1 (en) 2009-03-16 2010-03-16 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2012520342A JP2012520342A (ja) 2012-09-06
JP2012520342A5 true JP2012520342A5 (enExample) 2013-05-09

Family

ID=42111633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012500227A Pending JP2012520342A (ja) 2009-03-16 2010-03-16 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート

Country Status (8)

Country Link
US (2) US8575217B2 (enExample)
EP (1) EP2408443A1 (enExample)
JP (1) JP2012520342A (enExample)
CN (1) CN102427809B (enExample)
AU (1) AU2010224866C1 (enExample)
BR (1) BRPI1013878A2 (enExample)
CA (1) CA2755069A1 (enExample)
WO (1) WO2010106082A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101677126B1 (ko) 2008-05-20 2016-11-22 노이로제스엑스, 인코포레이티드 탄산염 프로드러그 및 그것의 사용 방법
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
US8466197B2 (en) * 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
RU2013133994A (ru) * 2010-12-21 2015-01-27 Нестек С.А. Способы и композиции, применимые для контроля глюкозы в крови животных
WO2013037984A1 (en) 2011-09-16 2013-03-21 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN103945839B (zh) * 2011-09-16 2018-02-09 根梅迪卡治疗公司 用于治疗代谢障碍的含抗炎剂和抗氧化剂缀合物的药物组合
AU2012312136B2 (en) * 2011-09-22 2017-06-29 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
US9273061B2 (en) * 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CA2876021C (en) * 2012-07-10 2020-09-22 Xpd Holdings, Llc Stabilized multi-functional antioxidant compounds and methods of use
EP2908849B1 (en) * 2012-08-31 2019-04-17 Board Of Regents, The University Of Texas System A method to improve pharmacokinetics of drugs
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
ES2562162T3 (es) 2012-10-02 2016-03-02 Reemtsma Cigarettenfabriken Gmbh Paquete para artículos relacionados con el tabaco y método de fabricación del paquete
CN105636583B (zh) 2013-09-13 2019-08-20 板井昭子 水溶液制剂及其制造方法
LT3066089T (lt) 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
EP3102557B1 (en) 2014-02-06 2020-01-29 Biocogent, LLC Improved compositions and methods comprising resveratrol
WO2016040342A1 (en) * 2014-09-08 2016-03-17 Kansas State University Research Foundation Early lactation administration of non-steroidal anti-inflammatory drugs to increase whole-lactation milk yield
WO2017015013A1 (en) * 2015-07-17 2017-01-26 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
KR101601685B1 (ko) * 2015-08-24 2016-03-09 여명바이오켐 주식회사 항산화 효과가 우수한 택시폴린 유도체 및 이를 함유하는 화장료 조성물
WO2018174839A1 (en) * 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
WO2018170765A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 Imd16基因的rna干涉载体及其应用
KR102048982B1 (ko) * 2017-11-10 2019-11-26 원광대학교 산학협력단 이데베논 유도체 화합물 및 이를 포함하는 화장료 조성물

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583602A (en) * 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
IT1134458B (it) 1980-11-26 1986-08-13 Real Sas Di Alberto Reiner Derivato della n-acetil-cisteina ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1194117B (it) * 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
IT1190987B (it) * 1982-09-07 1988-02-24 Pharma Edmond Srl Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono
IT1206515B (it) * 1983-08-09 1989-04-27 Guidotti & C Spa Labor N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
US5948769A (en) * 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
ES8609231A1 (es) 1985-12-03 1986-09-01 Farmhispania Procedimiento de obtencion del n-acetil-3(2-(acetiloxi)ben- zoilmercapto)alanina
ES8800144A1 (es) 1986-05-09 1987-11-01 Lasa Lab Procedimiento de obtencion de un tioester de la n-acetilcisteina y de sus sales de interes terapeutico
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
IT1213301B (it) 1986-07-14 1989-12-20 Zambon Spa Composizioni per il trattamento del le sindromi da ischemia e riperfusione
IT1228537B (it) 1987-07-30 1991-06-20 Magis Farmaceutici Derivati della cisteina ad azione espettorante
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
DE4327462A1 (de) 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
RU2054936C1 (ru) 1994-04-07 1996-02-27 Елизарова Евгения Павловна Мембраностабилизирующее средство для лечения больных с инсулинзависимым и инсулиннезависимым сахарным диабетом
DE4444051A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US5871769A (en) * 1996-01-18 1999-02-16 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of diabetes mellitus
CN1230178A (zh) * 1996-09-10 1999-09-29 麦地诺克斯公司 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AUPO612397A0 (en) * 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
ATE356113T1 (de) * 1997-05-14 2007-03-15 Atherogenics Inc Probucolbernsteinsäureester zur hemmung der expression von vcam-1
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
AU4543899A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US20020045580A1 (en) * 1999-11-24 2002-04-18 Sacks Meir S. Compositions for raising uric acid levels and methods of using same
US6258848B1 (en) * 1998-07-31 2001-07-10 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
AU6044699A (en) * 1998-09-17 2000-04-03 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment of glucose metabolism disorders
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
CA2377414A1 (en) * 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20080213785A1 (en) * 2000-04-20 2008-09-04 Andrew Levy Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals
US20080044399A1 (en) * 2000-04-20 2008-02-21 Andrew Levy Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6355666B1 (en) * 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6365176B1 (en) * 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
IT1319201B1 (it) * 2000-10-12 2003-09-26 Nicox Sa Farmaci per il diabete.
AU2002230543A1 (en) * 2000-11-02 2002-05-15 Nutrition 21, Inc. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
ATE532070T1 (de) * 2000-12-14 2011-11-15 Brigham & Womens Hospital Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
ATE279920T1 (de) 2000-12-28 2004-11-15 Fresenius Kabi Austria Gmbh Stabile infusionslösung von diclofenac-salzen, deren herstellung und verwendung
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
RS51031B (sr) * 2001-04-30 2010-10-31 Trommsdorff Gmbh & Co.Kg.Arzneimittel Farmaceutski aktivni estri uridina
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
EP1929998A3 (en) * 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
FR2835433B1 (fr) 2002-02-01 2006-02-17 Richard Lab M Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
JP2005527524A (ja) * 2002-03-14 2005-09-15 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｐｄｅ１１ａ阻害剤を用いる糖尿病の処置方法
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6960683B2 (en) * 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
JP4886297B2 (ja) * 2002-11-01 2012-02-29 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド ジオデート送達媒体
US8093292B2 (en) * 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
CN1233629C (zh) 2002-11-22 2005-12-28 贵州省中国科学院天然产物化学重点实验室 具有神经营养作用的硫酯类化合物及其它的合成方法和应用
MXPA02012315A (es) * 2002-12-13 2004-06-24 Univ Autonoma Metropolitana Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
AT500404A1 (de) * 2003-07-17 2005-12-15 Jsw Res Forschungslabor Gmbh Chemische verbindungen enthaltend tocopherol sowie zumindest einen weiteren pharmazeutischen wirkstoff
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US20070041925A1 (en) 2003-09-22 2007-02-22 Beiersdorf Ag Skin and hair care preparation containing a combination of protein hydrolyzates
US20070254055A1 (en) * 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
US20050143356A1 (en) * 2003-12-08 2005-06-30 Vanderbilt University Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
PT1574221E (pt) 2004-03-10 2007-07-09 Shimoda Biotech Pty Ltd Composições de diclofenac injectáveis estáveis
KR20070007837A (ko) * 2004-03-23 2007-01-16 라이프라인 뉴트러세티컬스 코포레이션 포유류에서 염증과 산화적 스트레스 완화를 위한 조성물 및방법
WO2005112914A2 (en) * 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
WO2005115455A2 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
JP4218601B2 (ja) 2004-06-29 2009-02-04 トヨタ自動車株式会社 圧縮着火内燃機関の空燃比センサ劣化判定システム
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
AU2005296565A1 (en) * 2004-10-22 2006-04-27 Kirin Beer Kabushiki Kaisha Transcriptional factor Nrf2 activator and food having the function of the same imparted thereto
US20060099279A1 (en) * 2004-11-09 2006-05-11 Council Of Scientific & Industrial Research Novel anti-diabetic herbal formulation
CN101072555B (zh) * 2004-12-08 2011-06-29 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
US20060276416A1 (en) * 2005-01-20 2006-12-07 Sirtris Pharmaceuticals, Inc. Methods and compositions for treating flushing and drug induced weight gain
US20080279897A1 (en) * 2005-01-21 2008-11-13 Medvet Science Pty. Ltd. Method of Treating Cellular Damage
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
EP1990049A3 (en) * 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID)
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
EP1877044A4 (en) * 2005-04-21 2009-09-02 Glenn A Goldstein AMIDE N-ACETYLCYSTEINE (AMIDE NAC) FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH OXIDATIVE STRESS
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7666898B2 (en) * 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
DE102005057178A1 (de) 2005-11-30 2007-07-19 Basf Ag Verwendung von Zinksalzen der Liponsäure zur Behandlung von Fettstoffwechselstörungen
JP2009521408A (ja) * 2005-12-02 2009-06-04 サートリス ファーマシューティカルズ， インコーポレイテッド Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
AU2006321942A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US20070231273A1 (en) * 2006-03-31 2007-10-04 Jie Wu Method for Decreasing Blood Glucose Levels
WO2007117048A1 (en) 2006-04-10 2007-10-18 Seoul National University Industry Foundation Inhibitors against g6pd enzyme for treating and preventing oxidative stress and/or inflammatory related diseases and method for screening the same
US20080015251A1 (en) * 2006-04-10 2008-01-17 Yissum Research Development Co., Of The Hebrew University Of Jerusalem Means and method for treating lipotoxicity and other metabolically related phenomena
EP2460517B1 (en) * 2006-04-28 2014-03-26 Joslin Diabetes Center, Inc. Reducing risk of type 2 diabetes (T2D)
JP5759672B2 (ja) * 2006-07-09 2015-08-05 テックフィールズ バイオケム カンパニー リミテッド アスピリンの正荷電水溶性プロドラッグ
WO2008012603A1 (en) * 2006-07-26 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
CA2657636C (en) * 2006-07-18 2021-11-09 Techfields Biochem Co. Ltd Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate
CN101500982A (zh) * 2006-07-25 2009-08-05 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性双氯芬酸前药
US20080139525A1 (en) * 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
JP5466006B2 (ja) * 2006-09-03 2014-04-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
WO2008127355A2 (en) * 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
US7498048B2 (en) * 2006-11-16 2009-03-03 Jose Angel Olalde Rangel Renal phyto-nutraceutical composition
DK2118279T3 (en) 2007-01-16 2018-02-26 Ipintl Llc HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
WO2008109702A1 (en) * 2007-03-08 2008-09-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009085695A1 (en) * 2007-12-31 2009-07-09 Horwitz Lawrence D Treatment or prevention of skin injury due to exposure to ultraviolet light
US20110009496A1 (en) 2008-01-08 2011-01-13 Sirtris Pharmaceuticas, Inc. Resveratrol formulations
WO2009137827A2 (en) * 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
CN102088965B (zh) 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法

Similar Documents

Publication Publication Date Title
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
NZ601126A (en) Voltage-gated sodium channel blockers
SE0401971D0 (sv) Piperidne derivatives
NZ601408A (en) Novel 3-hydroxy-5-arylisothiazole derivative
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
NO20090172L (no) Substituert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
RU2010139285A (ru) Производные пиридазина и их применение в качестве терапевтических агентов для лечения кожных нарушений
JP2011505347A5 (enExample)
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
SE9904413D0 (sv) Comminuted form
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
SE0401970D0 (sv) Novel compounds
NZ591814A (en) Pesticidal composition comprising an alpha-alkoxyphenyl acetic acid derivative and a neonicotinoid compound
WO2008088039A1 (ja) ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法
RU2010145526A (ru) Производное ацилтиомочевины или его соль и его применение
JP2011520836A5 (enExample)
CY1116664T1 (el) Χρηση ενος ινδαζολο-μεθοξυ-αλκανοϊκου οξεος για την παρασκευη μιας φαρμακευτικης συνθεσης